Department of Breast and Thyroid Surgery, Suining Central Hospital, Suining, Sichuan, China.
Front Endocrinol (Lausanne). 2023 Dec 5;14:1287101. doi: 10.3389/fendo.2023.1287101. eCollection 2023.
BACKGROUND: Breast cancer endocrine therapy research has become a crucial domain in oncology since hormone receptor-positive breast cancers have been increasingly recognized, and targeted therapeutic interventions have been advancing over the past few years. This bibliometric analysis attempts to shed light on the trends, dynamics, and knowledge hotspots that have shaped the landscape of breast cancer endocrine therapy research between 2003 and 2022. METHODS: In this study, we comprehensively reviewed the scientific literature spanning the above-mentioned period, which included publications accessible through the database of the Web of Science (WOS) and the National Center for Biotechnology Information (NCBI). Next, a systematic and data-driven analysis supported by sophisticated software tools was conducted, such that the core themes, prolific authors, influential journals, prominent countries, and critical citation patterns in the relevant research field can be clarified. RESULTS: A continuous and substantial expansion of breast cancer endocrine therapy research was revealed over the evaluated period. A total of 1,317 scholarly articles were examined. The results of the analysis suggested that research on endocrine therapy for breast cancer has laid a solid basis for the treatment of hormone receptor-positive breast cancer. From a geographical perspective, the US, the UK, and China emerged as the most active contributors, illustrating the global impact of this study. Furthermore, our analysis delineated prominent research topics that have dominated the discourse in the past two decades, including drug therapy, therapeutic efficacy, molecular biomarkers, and hormonal receptor interactions. CONCLUSION: This comprehensive bibliometric analysis provides a panoramic view of the ever-evolving landscape of breast cancer endocrine therapy research. The findings highlight the trajectory of past developments while signifying an avenue of vast opportunities for future investigations and therapeutic advancements. As the field continues to burgeon, this analysis will provide valuable guidance for to researchers toward pertinent knowledge hotspots and emerging trends, which can expedite the discoveries in the realm of breast cancer endocrine therapy.
背景:由于激素受体阳性乳腺癌的日益认识,乳腺癌内分泌治疗研究已成为肿瘤学的一个重要领域,近年来靶向治疗干预措施也在不断发展。本文献计量分析旨在阐明 2003 年至 2022 年间乳腺癌内分泌治疗研究的趋势、动态和知识热点。
方法:在这项研究中,我们全面回顾了上述时期的科学文献,这些文献可通过 Web of Science(WOS)和国家生物技术信息中心(NCBI)的数据库获得。接下来,我们使用复杂的软件工具进行了系统和数据驱动的分析,以阐明相关研究领域的核心主题、多产作者、有影响力的期刊、主要国家和关键引文模式。
结果:在所评估的期间,乳腺癌内分泌治疗研究呈现出持续且大量的扩展。共检查了 1317 篇学术文章。分析结果表明,针对乳腺癌内分泌治疗的研究为治疗激素受体阳性乳腺癌奠定了坚实的基础。从地理位置上看,美国、英国和中国是最活跃的贡献者,表明了这项研究的全球影响力。此外,我们的分析还描绘了过去二十年主导讨论的突出研究主题,包括药物治疗、治疗效果、分子生物标志物和激素受体相互作用。
结论:这项全面的文献计量分析提供了乳腺癌内分泌治疗研究不断发展的全景图。研究结果突出了过去发展的轨迹,同时也为未来的研究和治疗进展提供了广阔的机会。随着该领域的不断发展,本分析将为研究人员提供有价值的指导,了解相关的知识热点和新兴趋势,从而加速乳腺癌内分泌治疗领域的发现。
Front Endocrinol (Lausanne). 2023
Front Biosci (Landmark Ed). 2022-8-31
Front Endocrinol (Lausanne). 2023
Front Immunol. 2023
Front Microbiol. 2024-4-5
Wound Repair Regen. 2023
Front Endocrinol (Lausanne). 2022
Crit Rev Oncol Hematol. 2022-12
Cancers (Basel). 2022-11-7
Front Endocrinol (Lausanne). 2022